ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3
Application
US20260091033A1
Kind: A1
Apr 02, 2026
Inventors
Laurence LEGEAI-MALLET, Arnold MUNNICH, Patricia BUSCA, Florent BARBAULT
Abstract
The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.
CPC Classifications
A61K 31/506
A61K 31/519
A61K 38/177
A61K 38/179
B29C 48/0017
B29C 48/022
B32B 27/302
C08J 5/18
C08L 25/06
C08L 51/04
B29K 2025/06
B29K 2035/00
B29K 2201/00
B29L 2031/712
B32B 2262/06
B32B 2270/00
B32B 2439/70
C08J 2325/06
C08J 2401/00
C08J 2401/02
C08J 2425/06
C08J 2425/08
C08J 2447/00
C08L 2203/30
C08L 2205/02
C08L 2205/025
C08L 2205/03
C08L 2205/035
C08L 2205/16
Filing Date
2025-01-15
Application No.
19021632